{
    "nctId": "NCT01231802",
    "briefTitle": "Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer",
    "officialTitle": "A Comparative, Multicenter, Open-Label, Randomized, Phase 2 Study of the Safety and Antitumor Activity of Oral Eniluracil + 5 Fluorouracil + Leucovorin Versus Capecitabine Monotherapy in Subjects With Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 140,
    "primaryOutcomeMeasure": "Progression-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed metastatic (Stage IV) adenocarcinoma of the breast\n* Prior exposure to anthracyclines either in the neoadjuvant/adjuvant setting, or as treatment for metastatic disease\n* Either evidence of a recurrence or development of metastatic disease at least 12 months after the last dose of a taxane as neoadjuvant/adjuvant therapy, or evidence of disease progression while receiving a taxane for metastatic disease\n* ECOG Performance Status of 0 or 1\n* Measurable disease according to RECIST 1.1 Criteria\n* Adequate renal, hematologic, and hepatic function\n* Negative pregnancy test and willing to use effective contraception\n* Willing to avoid any other dose or form (iv, oral, or topical) of 5 FU or related derivatives for 8 weeks following the last dose of eniluracil\n* Willing to be closely monitored for changes in coagulation parameters (prothrombin time and/or international normalized ratio \\[INR\\] values) if receiving concomitant warfarin\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Prior treatment with capecitabine\n* More than one prior chemotherapy regimen for metastatic disease\n* Prior radiation must not have included \u2265 30% of major bone marrow-containing areas (pelvis, lumbar spine). If prior radiation was \\< 30%, then a minimum interval of 6 weeks must be allowed between the last radiation treatment and administration of either study arm.\n* Currently receiving anti-cancer therapy\n* Residual \u2265 Grade 2 clinically significant side effects (excluding alopecia) associated with prior radiotherapy, chemotherapy, and investigational treatments\n* Unstable CNS metastases. However, subjects that are asymptomatic and off systemic steroids and anticonvulsants for at least 3 months are not excluded.\n* Malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, ulcerative colitis, recent history of GI bleeding or perforation\n* History of other malignancy, except subjects who have been disease-free for 5 years or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma\n* Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety\n* Known history or clinical evidence of leptomeningeal carcinomatosis\n* Active or uncontrolled infection\n* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent\n* Known history of uncontrolled or symptomatic angina, arrhythmia or congestive heart failure\n* Concurrent treatment with an investigational agent\n* Use of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication\n* Taking phenytoin\n* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to capecitabine, fluorouracil, leucovorin, or any excipients\n* Known dihydropyrimidine dehydrogenase (DPD) deficiency",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}